The revision includes a welcome move toward digital documentation, electronic labelling, and remote audit tools, which can cut down on unnecessary paperwork, and result in reduced administrative burden and costs. It also allows for earlier dialogue between manufacturers and regulators. And it brings in faster pathways for truly innovative or “orphan” devices that address unmet medical needs, an area that has been absent in the EU regulatory framework until now.
